Edgestream Partners L.P. bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 2,203 shares of the pharmaceutical company’s stock, valued at approximately $1,152,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. MADDEN SECURITIES Corp purchased a new position in shares of Vertex Pharmaceuticals in the third quarter valued at about $26,000. Meeder Asset Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $26,000. Community Financial Services Group LLC bought a new stake in shares of Vertex Pharmaceuticals in the second quarter worth about $26,000. Elevation Wealth Partners LLC raised its holdings in shares of Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Finally, Pingora Partners LLC bought a new position in Vertex Pharmaceuticals during the second quarter valued at $32,000. 90.96% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at Vertex Pharmaceuticals
In other Vertex Pharmaceuticals news, EVP Charles F. Wagner, Jr. sold 15,286 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the completion of the sale, the executive vice president directly owned 31,764 shares in the company, valued at approximately $17,402,542.68. The trade was a 32.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of the company’s stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director directly owned 1,109 shares of the company’s stock, valued at approximately $607,576.74. This represents a 47.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 16,557 shares of company stock worth $9,071,071 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
Vertex Pharmaceuticals Trading Down 1.1%
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the company earned $4.80 earnings per share. Vertex Pharmaceuticals’s revenue was up 11.8% on a year-over-year basis. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have commented on VRTX shares. Weiss Ratings cut shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. Barclays lifted their price target on shares of Vertex Pharmaceuticals from $617.00 to $626.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Daiwa Securities Group upped their price objective on Vertex Pharmaceuticals from $555.00 to $556.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Leerink Partners started coverage on shares of Vertex Pharmaceuticals in a report on Monday, September 21st. They set an “outperform” rating and a $594.00 price objective for the company. Finally, Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $596.44.
View Our Latest Stock Analysis on VRTX
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
